An analysis of neonatal blood spots has identified such somatic RAS pathway mutations (most commonly in PTPN11, NRAS and KRAS) in 38% of children (n = 34) without Noonan Syndrome but presenting with JMML at a median age of 1.5 years [206]. Here, KRAS is linked to juvenile myelomonocytic leukemia.